Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues
European Journal of Immunology, 07/11/2012
Schweizer A et al. – The authors show the development of a new therapeutic compound for targeting CD22 on human B cells, both for B–cell lymphoma, as well as for B cell–mediated autoimmune diseases.



